Second, several important tumor characteristics (e.g. human epidermal growth factor receptor-2), the application of therapy (neoadjuvant and adjuvant), and patient outcome (recurrence and metastasis) variables are unrecorded in the SEER database, thus we could not adjust these potential confounding factors. Here, ERBB2 is linked to neoplasm.